...Good morning and thank you for joining us. This is Ian Mcdonald, Chief Executive Officer of Bright Minds Biosciences. Today we're reporting the top-line data from the Phase 2 breakthrough study of BMB-101 in adults with drug resistant absence seizures. As well as developmental and epileptic encephalopathies, these are patients with highly refractory disease and substantial treatment history, and the results you'll see today should be interpreted in that context. Before we begin, please note that this presentation is current as of January 2026 and contains forward-looking statements within the meaning of applicable securities law, including statements about clinical development plans, timelines, regulatory pathways, and potential safety and efficacy of BMB-101. Actual results may differ materially due to risks and uncertainties described in our filings. Including our annual report on Form 40-F and other SEC and SEDAR+ disclosures. This presentation is summary in nature, and we do not undertake...
